Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 753 - 760 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC3968 | TAK-715 |
|
Inhibitor of p38 MAPK (IC<sub>50</sub> = 7.1 nM for p38 MAPK<span class='symbol'>α</span>). Also inhibits Wnt-3a-stimulated <span class='symbol'>β</span>-catenin signaling. Inhibits 22 kinases by more than 80%, including CK1<span class='symbol'>δ</span>/<span class='symbol'>ε</span>. Anti-inflammatory and anti-rheumatoid arthritis agent. Orally bioavailable.
|
|
| BCC3970 | Flumatinib mesylate |
|
Flumatinib (HH-GV-678) ，a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.
|
|
| BCC3971 | PF-431396 |
|
Dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively). Promotes osteoblast recruitment and activity, and stimulates bone formation in ovariectomized rats.
|
|
| BCC3981 | SW033291 |
|
High affinity 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor (Ki = 0.1 nM). Increases PGE2 levels in A549 cells in vitro, as well as in bone marrow, colon, lung and liver in mice. Promotes hematopoiesis, recovery from DSS-induced colitis, and hepatocyte proliferation after partial hepatectomy in mice.
|
|
| BCC3983 | SR-9243 |
|
Selective LXR inverse agonist. Exhibits no significant activity at other nuclear receptors at maximally effective concentration. Inhibits the Warburg effect and lipogenesis by down-regulation of LXR-mediated gene expression. Selectively reduces cell viability and induces apoptosis in cancer cell lines in vitro. Suppresses hepatic steatosis and inhibits growth of tumor xenografts in mice.
|
|
| BCC3987 | ML 239 |
|
Breast cancer stem cell inhibitor (IC<sub>50</sub> = 1.16 <span class='symbol'>μ</span>M). Exhibits 24-fold selectivity for breast cancer stem cells over normal mammary epithelial cells. Also cytotoxic towards MDA-MB-231 breast cancer cells <em>in vitro</em>.
|
|
| BCC3995 | ME0328 |
|
Inhibitor of PARP-3 (IC<sub>50</sub> = 0.89 <span class='symbol'>μ</span>M). Displays selectivity for PARP-3 over PARP-1, PARP-2 and other ARDT enzymes (IC<sub>50</sub> values are 6.3, 10.8 and >30 <span class='symbol'>μ</span>M respectively). Enhances CRISPR-Cas9-mediated <em>HER2</em> mutation frequency, resulting in increased reduction in proliferation of HER2-positive breast cancer cells. Cell permeable.
|
|
| BCC4000 | NSC697923 |
|
Selective inhibitor of the E2 ubiquitin (Ub) conjugating enzyme UBE2N (Ubc13). Inhibits UBE2N-Ub conjugation and activity of the UBE2N-Ueva1A complex. Has no effect on UbcH5c activity. Inhibits NF-<span class='symbol'>κ</span>B activation in diffuse large B-cell lymphoma (DLBCL) cells. Inhibits cell growth and induces apoptosis in DLBCL and neuroblastoma (NB) cell lines. Supresses NB cell xenograft tumor growth <em>in vivo</em>.
|
|